Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Active Trials
    1(50%)

    Phase Distribution

    Phase 2
    1
    50%
    Phase 3
    1
    50%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    1

    Late Stage

    Phase Distribution2 total trials
    Phase 2Efficacy & side effects
    1(50.0%)
    Phase 3Large-scale testing
    1(50.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 1 finished

    Non-Completion Rate

    100.0%

    1 ended early

    Currently Active

    1

    trials recruiting

    Total Trials

    2

    all time

    Status Distribution
    Active(1)
    Terminated(1)

    Detailed Status

    Recruiting1
    Withdrawn1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    2
    Active
    1
    Success Rate
    N/A
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 21 (50.0%)
    Phase 31 (50.0%)

    Trials by Status

    recruiting150%
    withdrawn150%

    Recent Activity

    1 active trials
    Showing 2 of 2
    recruitingphase_3

    Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

    NCT06593431
    withdrawnphase_2

    Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

    NCT04931420

    Clinical Trials (2)

    Showing 2 of 2 trials
    NCT06593431Phase 3

    Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

    Recruiting
    NCT04931420Phase 2

    Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

    Withdrawn

    All 2 trials loaded

    Drug Details

    Intervention Type
    Radiation
    Total Trials
    2